Zealand Pharma Submits New Drug Application to the US FDA for Glepaglutide in Short Bowel Syndrome
Copenhagen, Denmark, December 22, 2023– Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Biotechnology | Denmark Health | Drugs & Pharmacology | New Drug Applications | New Zealand Health | Pharmaceuticals